MedTrace Logo

Dose-finding Study of MT-1303

NCT01742052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 415

Last updated 2016-09-14

No results posted yet for this study

Summary

The primary objectives of the study are:

* To evaluate the effects of three oral doses of MT-1303 compared to placebo given for a period of 24 weeks in subjects with relapsing-remitting multiple sclerosis (RRMS) on MRI parameters
* To evaluate the safety and tolerability of three oral doses of MT-1303 compared to placebo given for a period of 24 weeks in subjects with RRMS.

Conditions

  • Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

MT-1303-Low

DRUG

MT-1303-Middle

DRUG

MT-1303-High

DRUG

Placebo

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-07-31
Completion
2014-10-31

Countries

  • Belgium
  • Bulgaria
  • Canada
  • Croatia
  • Czechia
  • Finland
  • Germany
  • Hungary
  • Italy
  • Lithuania
  • Poland
  • Russia
  • Serbia
  • Spain
  • Switzerland
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01742052 on ClinicalTrials.gov